Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Dev Immunol. 2012;2012:854846. doi: 10.1155/2012/854846. Epub 2012 Nov 25.

Mesenchymal stem cells as immunomodulators in a vascularized composite allotransplantation.

Author information

1
Center for Vascularized Composite Allotransplantation, Kaohsiung Chang Gung Memorial Hospital, Taiwan. t1207816@ms22.hinet.net

Abstract

Vascularized composite allotransplantations (VCAs) are not routinely performed for tissue reconstruction because of the potentially harmful adverse effects associated with lifelong administration of immunosuppressive agents. Researchers have been eagerly seeking alternative methods that circumvent the long-term use of immunosuppressants. Mesenchymal stem cells (MSCs) show promise as an immunomodulatory therapeutic agent and are currently being tested in preclinical and clinical settings as therapies for autoimmune disorders or transplant rejection. The mechanisms by which MSCs modulate the immune response are still under thorough investigation, but these most likely involve expression of local factors influencing T-cell regulation, modulation of cytokine expression (e.g., IL-10, TGF-β, TNF-α, INF-γ, etc.), and interactions with dendritic or antigen presenting cells. In this paper, we summarize the current understanding of immunomodulation achieved by MSC therapies and introduce a possible outline for future clinical applications in VCA.

PMID:
23227090
PMCID:
PMC3514826
DOI:
10.1155/2012/854846
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center